NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
Altasciences Appoints New General Manager, Clinical Operations
Altasciences ernennt neuen General Manager, Clinical Operations
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia
Angel Reyes Joins Altasciences as General Manager of CDMO Services
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Altasciences Receives 2023 CRO Leadership Award for Capabilities
Altasciences is supporting Alzamend Neuro, Inc. in advancing a novel treatment for dementia related to Alzheimer’s disease. In addition to having conducted Alzamend’s Phase IIa multiple ascending dose (MAD) clinical trial in healthy subjects, Altasciences is continuing to provide clinical monitoring, project management, biostatistics, pharmacokinetics (PK), bioanalysis, and medical writing solutions as the product candidate is evaluated in Alzheimer’s patients.
Proscia, a provider of digital and computational pathology solutions, announced that Altasciences, a contract research organization (CRO), has chosen Proscia’s Concentriq for Research to help its sponsors advance life-saving therapeutics.
Altasciences Expands Laboratory Capabilities in Columbia